Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kerendia
Pharma
Bayer touts results for Kerendia in phase 3 heart failure trial
Bayer unveiled trial data that showed Kerendia reduced the risk of cardiovascular death by 16% compared to placebo in patients with HFmrEF or HFpEF.
Kevin Dunleavy
Sep 2, 2024 1:00am
Bayer charts growth course amid Xarelto's ongoing sales descent
Aug 6, 2024 12:29pm
Bayer's Kerendia excels in P3 trial of heart failure patients
Aug 5, 2024 10:24am
Bayer de-emphasizes the impact of Roche's Vabysmo on Eylea sales
May 14, 2024 11:46am
In push to boost Kerendia, Bayer adds 3 heart failure trials
Sep 1, 2023 11:03am
Bayer's new CEO Bill Anderson weighs structural change
Aug 8, 2023 11:15am
